Codice QR

CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal prognosis. Although combined treatment with gemcitabine and albumin-bound paclitaxel has improved the prognosis of PDAC, both intrinsic and acquired chemoresistance remain as severe hurtles towards impr...

Descrizione completa

Salvato in:
Autori principali: Siyuan Zeng, Bin Lan, Xiaofan Ren, Shuman Zhang, Daniel Schreyer, Markus Eckstein, Hai Yang, Nathalie Britzen-Laurent, Andreas Dahl, Debabrata Mukhopadhyay, David Chang, Isabella Kutschick, Susanne Pfeffer, Peter Bailey, Andrew Biankin, Robert Grützmann, Christian Pilarsky
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMC 2022-08-01
Serie:Journal of Experimental & Clinical Cancer Research
Soggetti:
CRISPR-Cas9
CDK7
Gemcitabine
Paclitaxel
FOLFIRINOX
THZ1
Accesso online:https://doi.org/10.1186/s13046-022-02443-w
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi